New Diagnostic Test Helping in the Fight Against Ovarian Cancer

A new test for ovarian cancer was demonstrated to be 99% to 100% accurate over 100 patient samples by Researchers at Georgia Institute of Technology. This new diagnostic technique is able to test a single drop of blood serum using JEOL's AccuTOF™-DART® mass spectrometer.

For the ovarian cancer test in development, Dr. Facundo Fernandez, Assoc. Professor in the School of Chemistry and Biochemistry and coworkers at Georgia Institute of Technology, analyzed a sample from a single drop of blood serum from each test subject by using the hot helium plasma created by the DART ion source. The mass spectrometer then instantly analyzed the relative abundance of metabolites, or small molecules in the serum. Specially developed techniques were used to sort sets of metabolites found in cancerous plasma from those found in healthy samples. The metabolic changes were mapped and proved to be 99% to 100% accurate in distinguishing sera from women with ovarian cancer from normal controls without registering a single false positive or false negative.

The group is currently in the midst of conducting the next set of assays, this time with 500 patients.

Meanwhile as test preparations proceed at Georgia Tech’s Ovarian Cancer Institute, Fernandez said, "The caveat is we don't currently have 500 patients with the same type of ovarian cancer, so we're going to look at other types of ovarian cancer. It's possible that there are also signatures for other cancers, not just ovarian, so we're also going to be using the same approach to look at other types of cancers. We'll be working with collaborators in Atlanta and elsewhere."

If further testing confirms the ability to accurately detect ovarian cancer by analyzing metabolites in the serum of women, doctors will be able detect the disease early and save many lives.

“This is the most accurate diagnostic test for ovarian cancer thus far reported. We are currently expanding the number of samples examined in order to demonstrate the robustness of the test prior to applying for FDA approval for clinical use,” the website for the Ovarian Cancer Institute states.

The results can be found online in the journal Cancer Epidemiology, Biomarkers, & Prevention Research in the paper entitled Rapid Mass Spectrometric Metabolic Profiling of Blood Sera Detects Ovarian Cancer with High Accuracy.